Drug Profile
NBP 607-QIV
Alternative Names: Cell culture derived quadrivalent inactivated subunit influenza vaccine - SK Bioscience; NBP 607-QIV; NBP 607-quadrivalent; Quadrivalent inactivated cell culture derived influenza vaccine - SK Bioscience; Sky Cell Flu; SKYCellflu quadrivalentLatest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator SK Chemicals
- Developer SK Bioscience
- Class Influenza virus vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 08 Oct 2021 Launched for Influenza virus infections (In adolescents, In children, In infants, Prevention) in South Korea (IM) before October 2021 (SK Bioscience website, October 2021)
- 15 Oct 2018 SK Bioscience plans a phase III trial for Influenza virus infections (In infants, In children) in October 2018 (NCT03704740)
- 02 Jul 2018 SK Chemicals divested the vaccine business portfolio to a newly formed subsidiary SK Bioscience